Cargando…
mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study,...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402682/ https://www.ncbi.nlm.nih.gov/pubmed/34452043 http://dx.doi.org/10.3390/vaccines9080918 |
_version_ | 1783745849583468544 |
---|---|
author | Fabricius, Dorit Ludwig, Carolin Scholz, Judith Rode, Immanuel Tsamadou, Chrysanthi Jacobsen, Eva-Maria Winkelmann, Martina Grempels, Aline Lotfi, Ramin Janda, Aleš Körper, Sixten Adler, Guido Debatin, Klaus-Michael Schrezenmeier, Hubert Jahrsdörfer, Bernd |
author_facet | Fabricius, Dorit Ludwig, Carolin Scholz, Judith Rode, Immanuel Tsamadou, Chrysanthi Jacobsen, Eva-Maria Winkelmann, Martina Grempels, Aline Lotfi, Ramin Janda, Aleš Körper, Sixten Adler, Guido Debatin, Klaus-Michael Schrezenmeier, Hubert Jahrsdörfer, Bernd |
author_sort | Fabricius, Dorit |
collection | PubMed |
description | To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study, we compared immunological responses in 144 individuals vaccinated with the mRNA vaccines BNT162b2 or mRNA-1273 and the vector vaccine ChAdOx1-nCoV-19, either alone, in combination, or in the context of COVID-19-convalescence. Unvaccinated COVID-19-convalescent subjects served as a reference. We found that cellular and serological immune responses, including neutralizing capacity against VOCs, were significantly stronger with mRNA vaccines as compared with COVID-19-convalescent individuals or vaccinated individuals receiving the vector vaccine ChAdOx1-nCoV-19. Booster immunizations with mRNA vaccines triggered strong and broadly neutralizing antibody and IFN-γ responses in 100% of vaccinated individuals investigated. This effect was particularly strong in COVID-19-convalescent and ChAdOx1-nCoV-19-primed individuals, who were characterized by comparably moderate cellular and neutralizing antibody responses before mRNA vaccine booster. Heterologous vaccination regimes and convalescent booster regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs. Furthermore, such regimes may facilitate rapid (re-)qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies. |
format | Online Article Text |
id | pubmed-8402682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84026822021-08-29 mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects Fabricius, Dorit Ludwig, Carolin Scholz, Judith Rode, Immanuel Tsamadou, Chrysanthi Jacobsen, Eva-Maria Winkelmann, Martina Grempels, Aline Lotfi, Ramin Janda, Aleš Körper, Sixten Adler, Guido Debatin, Klaus-Michael Schrezenmeier, Hubert Jahrsdörfer, Bernd Vaccines (Basel) Article To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study, we compared immunological responses in 144 individuals vaccinated with the mRNA vaccines BNT162b2 or mRNA-1273 and the vector vaccine ChAdOx1-nCoV-19, either alone, in combination, or in the context of COVID-19-convalescence. Unvaccinated COVID-19-convalescent subjects served as a reference. We found that cellular and serological immune responses, including neutralizing capacity against VOCs, were significantly stronger with mRNA vaccines as compared with COVID-19-convalescent individuals or vaccinated individuals receiving the vector vaccine ChAdOx1-nCoV-19. Booster immunizations with mRNA vaccines triggered strong and broadly neutralizing antibody and IFN-γ responses in 100% of vaccinated individuals investigated. This effect was particularly strong in COVID-19-convalescent and ChAdOx1-nCoV-19-primed individuals, who were characterized by comparably moderate cellular and neutralizing antibody responses before mRNA vaccine booster. Heterologous vaccination regimes and convalescent booster regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs. Furthermore, such regimes may facilitate rapid (re-)qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies. MDPI 2021-08-18 /pmc/articles/PMC8402682/ /pubmed/34452043 http://dx.doi.org/10.3390/vaccines9080918 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fabricius, Dorit Ludwig, Carolin Scholz, Judith Rode, Immanuel Tsamadou, Chrysanthi Jacobsen, Eva-Maria Winkelmann, Martina Grempels, Aline Lotfi, Ramin Janda, Aleš Körper, Sixten Adler, Guido Debatin, Klaus-Michael Schrezenmeier, Hubert Jahrsdörfer, Bernd mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
title | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
title_full | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
title_fullStr | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
title_full_unstemmed | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
title_short | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
title_sort | mrna vaccines enhance neutralizing immunity against sars-cov-2 variants in convalescent and chadox1-primed subjects |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402682/ https://www.ncbi.nlm.nih.gov/pubmed/34452043 http://dx.doi.org/10.3390/vaccines9080918 |
work_keys_str_mv | AT fabriciusdorit mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT ludwigcarolin mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT scholzjudith mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT rodeimmanuel mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT tsamadouchrysanthi mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT jacobsenevamaria mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT winkelmannmartina mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT grempelsaline mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT lotfiramin mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT jandaales mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT korpersixten mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT adlerguido mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT debatinklausmichael mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT schrezenmeierhubert mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT jahrsdorferbernd mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects |